<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005851</url>
  </required_header>
  <id_info>
    <org_study_id>1495.00</org_study_id>
    <secondary_id>NCI-2012-00581</secondary_id>
    <secondary_id>1495.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00005851</nct_id>
  </id_info>
  <brief_title>Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer</brief_title>
  <official_title>Phase I/II Study of HLA-Matched Non-Myeloablative Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation as Treatment for Patients With Metastatic Renal Cell Carcinoma. A Multi-Center Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for doing this study is to see if cancer will respond to immune therapy after&#xD;
      transplantation of blood stem cells (from the bone marrow) using a new kind of treatment&#xD;
      regimen that is less toxic than that previously used for blood stem cell transplants. This&#xD;
      type of transplant uses much less chemotherapy and radiation than standard bone marrow&#xD;
      transplants. The treatment consists of medications that weaken the immune system so it&#xD;
      doesn't reject the donor's marrow cells. Researchers hope that the immune cells from the&#xD;
      donor will attack the tumor. This is called a &quot;graft versus tumor&quot; effect and has been seen&#xD;
      in other types of cancer. In addition, 65 days or more after the transplant the patient may&#xD;
      be eligible for an immune treatment that uses additional immune cells from the donor to&#xD;
      increase the effect of the stem cells against the cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether mixed or full donor hematopoietic chimerism can be safely established&#xD;
      using a non-myeloablative conditioning regimen.&#xD;
&#xD;
      II. To determine whether mixed chimerism can be safely converted to full donor hematopoietic&#xD;
      chimerism by infusions of donor lymphocytes (DLI).&#xD;
&#xD;
      III. To evaluate potential efficacy of this approach as a treatment for metastatic renal&#xD;
      cancer.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days -4 to&#xD;
      -2 and undergo low-dose total-body irradiation (TBI) on day 0.&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.&#xD;
&#xD;
      IMMUNOSUPRESSION: Patients receive cyclosporine orally (PO) twice daily (BID) or IV once&#xD;
      daily (QD) or BID on days -3 to 35 with taper to day 56, and mycophenolate mofetil PO or IV&#xD;
      over 2 hours thrice daily (TID) on days 0-40.&#xD;
&#xD;
      DLI: Patients with stable mixed chimerism on day 56 with no evidence of graft-vs-host disease&#xD;
      (GVHD) may receive escalating doses of non-mobilized DLI over 30 minutes. Patients may&#xD;
      receive up to 4 DLIs at escalating doses if there is disease progression with no evidence of&#xD;
      GVHD.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">September 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>True response rate (complete response [CR] or partial response [PR]) greater than the 15% achievable with standard therapy</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>If 6 or more out of 25 patients achieve a CR or PR, then there is at least 80% confidence that the true response rate exceeds 15% and that this approach is potentially efficacious.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>Within 200 days of transplant</time_frame>
    <description>Defined as death before day 200 not related to progression of disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of grade IV acute GVHD</measure>
    <time_frame>Up to 90 days after last T-cell infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be examined separately and reported in a descriptive manner and confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be examined separately and reported in a descriptive manner and confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myelosuppression after initial PBSC infusion</measure>
    <time_frame>Up to 2 months post-transplant</time_frame>
    <description>Defined as absolute neutrophil count &lt; 500 for &gt; 2 days, platelets &lt; 20,000 for &gt; 2 days. Will be examined separately and reported in a descriptive manner and confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of aplasia after DLI</measure>
    <time_frame>Until 2 months post-transplant</time_frame>
    <description>Will be examined separately and reported in a descriptive manner and confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades 2-4 acute GVHD after DLI</measure>
    <time_frame>Up to 90 days after last T-cell infusion</time_frame>
    <description>Will be examined separately and reported in a descriptive manner and confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades chronic extensive GVHD after DLI</measure>
    <time_frame>Up to 90 days after last T-cell infusion</time_frame>
    <description>Will be examined separately and reported in a descriptive manner and confidence intervals will be presented for all estimates.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Recurrent Renal Cell Cancer</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (nonmyeloablative donor PBSC transplantation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.&#xD;
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.&#xD;
IMMUNOSUPRESSION: Patients receive cyclosporine PO BID or IV QD or BID on days -3 to 35 with taper to day 56, and mycophenolate mofetil PO or IV over 2 hours TID on days 0-40.&#xD;
DLI: Patients with stable mixed chimerism on day 56 with no evidence of GVHD may receive escalating doses of non-mobilized DLI over 30 minutes. Patients may receive up to 4 DLIs at escalating doses if there is disease progression with no evidence of GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nonmyeloablative donor PBSC transplantation)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (nonmyeloablative donor PBSC transplantation)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo nonmyeloablative allogeneic PBSC transplantation</description>
    <arm_group_label>Treatment (nonmyeloablative donor PBSC transplantation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (nonmyeloablative donor PBSC transplantation)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (nonmyeloablative donor PBSC transplantation)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo nonmyeloablative allogeneic PBSC transplantation</description>
    <arm_group_label>Treatment (nonmyeloablative donor PBSC transplantation)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <description>Undergo DLI</description>
    <arm_group_label>Treatment (nonmyeloablative donor PBSC transplantation)</arm_group_label>
    <other_name>ALLOLYMPH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (nonmyeloablative donor PBSC transplantation)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed stage IV renal cancer who have stable&#xD;
             (including those rendered to be in remission) or progressive disease&#xD;
&#xD;
          -  Human lymphocyte antigen (HLA) genotypically identical related donor willing to&#xD;
             undergo leukapheresis initially for collection of peripheral blood stem cells (PBSC)&#xD;
             and subsequently for collection of peripheral blood mononuclear cells (PBMC)&#xD;
&#xD;
          -  Ionized calcium level within normal limits&#xD;
&#xD;
          -  DONOR: HLA genotypically identical family member (excluding identical twins)&#xD;
&#xD;
          -  DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis&#xD;
&#xD;
          -  DONOR: Donor must have adequate veins for leukapheresis or agree to placement of&#xD;
             central venous catheter (femoral, subclavian)&#xD;
&#xD;
          -  DONOR: Age &lt; 75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have positive serologies for human immunodeficiency virus (HIV)1 and 2,&#xD;
             human T-lymphotropic virus (HTLV)-1&#xD;
&#xD;
          -  Patients unwilling to use contraceptive techniques during and for 12 months following&#xD;
             treatment&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0; the Fred Hutchinson Cancer Research Center (FHCRC) Patient&#xD;
             Care Conference (PCC) may approve patients with elevated serum creatinine following&#xD;
             presentation and approval; centers outside the FHCRC that have a PCC or equivalent&#xD;
             should obtain their institutional approval; if there is not a comparable group at the&#xD;
             institution, please contact the FHCRC Principal Investigator for FHCRC approval&#xD;
             through PCC&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 50%; ejection fraction is required if the patient has a&#xD;
             history of anthracyclines or history of cardiac disease&#xD;
&#xD;
          -  Diffusion capacity of carbon monoxide (DLCO) &lt; 50% of predicted, total lung capacity&#xD;
             (TLC) &lt; 50%, forced expiratory volume in one second (FEV1) &lt; 50%&#xD;
&#xD;
          -  Liver function tests including total bilirubin, serum glutamate pyruvate transaminase&#xD;
             (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) &gt; 2 x the upper limit of&#xD;
             normal unless due to the malignancy&#xD;
&#xD;
          -  Karnofsky score &lt; 80&#xD;
&#xD;
          -  Brain metastasis&#xD;
&#xD;
          -  Ongoing active bacterial, viral or fungal infection&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Patients with other active non-hematologic malignancies (except non-melanoma skin&#xD;
             cancers)&#xD;
&#xD;
          -  Patients with a history of other non-hematologic malignancies (except non-melanoma&#xD;
             skin cancers) currently in a complete remission, who are less than 5 years from the&#xD;
             time of complete remission, and have a &gt; 20% risk of disease recurrence&#xD;
&#xD;
          -  The addition of cytotoxic agents for &quot;cytoreduction&quot; with the exception of Gleevec&#xD;
             (imatinib mesylate), cytokine therapy, hydroxyurea, low dose cytarabine, chlorambucil,&#xD;
             or rituxan will not be allowed within three weeks of the initiation of conditioning&#xD;
&#xD;
          -  DONOR: Age less than 12 years&#xD;
&#xD;
          -  DONOR: Pregnancy&#xD;
&#xD;
          -  DONOR: Infection with HIV&#xD;
&#xD;
          -  DONOR: Inability to achieve adequate venous access&#xD;
&#xD;
          -  DONOR: Known allergy to G-CSF&#xD;
&#xD;
          -  DONOR: Current serious systemic illness&#xD;
&#xD;
          -  DONOR: Failure to meet criteria for donation as described in the Standard Practice&#xD;
             Guidelines of the institution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Sandmaier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers-Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

